CRDF Quote, Financials, Valuation and Earnings

Allogene Therapeutics has a net margin of -12324.77% compared to Cardiff Oncology's net margin of -295454.55%. Cardiff Oncology's return on equity of -77.18% beat Allogene Therapeutics's return on equity of -52.73%.

Cardiff Oncology has a consensus price target of $12.07, signalling upside risk potential of 173.11%. On the other hand Allogene Therapeutics has an analysts' consensus of $8.15 which suggests that it could grow by 562.6%. Given that Allogene Therapeutics has higher upside potential than Cardiff Oncology, analysts believe Allogene Therapeutics is more attractive than Cardiff Oncology.

Cardiff Oncology has a beta of 1.516, which suggesting that the stock is 51.624% more volatile than S&P 500. In comparison Allogene Therapeutics has a beta of 0.308, suggesting its less volatile than the S&P 500 by 69.171%.

Cardiff Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allogene Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology pays -- of its earnings as a dividend. Allogene Therapeutics pays out -- of its earnings as a dividend.

Cardiff Oncology quarterly revenues are $109K, which are larger than Allogene Therapeutics quarterly revenues of $22K. Cardiff Oncology's net income of -$13.4M is higher than Allogene Therapeutics's net income of -$59.7M. Notably, Cardiff Oncology's price-to-earnings ratio is -- while Allogene Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology is 399.21x versus 2,916.87x for Allogene Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals has a net margin of -12324.77% compared to Cardiff Oncology's net margin of --. Cardiff Oncology's return on equity of -77.18% beat Armata Pharmaceuticals's return on equity of --.

Cardiff Oncology has a consensus price target of $12.07, signalling upside risk potential of 173.11%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $9.00 which suggests that it could grow by 281.36%. Given that Armata Pharmaceuticals has higher upside potential than Cardiff Oncology, analysts believe Armata Pharmaceuticals is more attractive than Cardiff Oncology.

Cardiff Oncology has a beta of 1.516, which suggesting that the stock is 51.624% more volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.224%.

Cardiff Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Cardiff Oncology quarterly revenues are $109K, which are larger than Armata Pharmaceuticals quarterly revenues of --. Cardiff Oncology's net income of -$13.4M is lower than Armata Pharmaceuticals's net income of -$6.5M. Notably, Cardiff Oncology's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology is 399.21x versus 1,000.03x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Mustang Bio has a net margin of -12324.77% compared to Cardiff Oncology's net margin of --. Cardiff Oncology's return on equity of -77.18% beat Mustang Bio's return on equity of --.

Cardiff Oncology has a consensus price target of $12.07, signalling upside risk potential of 173.11%. On the other hand Mustang Bio has an analysts' consensus of -- which suggests that it could grow by 4424.89%. Given that Mustang Bio has higher upside potential than Cardiff Oncology, analysts believe Mustang Bio is more attractive than Cardiff Oncology.

Cardiff Oncology has a beta of 1.516, which suggesting that the stock is 51.624% more volatile than S&P 500. In comparison Mustang Bio has a beta of 2.165, suggesting its more volatile than the S&P 500 by 116.485%.

Cardiff Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mustang Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology pays -- of its earnings as a dividend. Mustang Bio pays out -- of its earnings as a dividend.

Cardiff Oncology quarterly revenues are $109K, which are larger than Mustang Bio quarterly revenues of --. Cardiff Oncology's net income of -$13.4M is lower than Mustang Bio's net income of -$153K. Notably, Cardiff Oncology's price-to-earnings ratio is -- while Mustang Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology is 399.21x versus -- for Mustang Bio. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -12324.77% compared to Cardiff Oncology's net margin of -35.79%. Cardiff Oncology's return on equity of -77.18% beat Protalix BioTherapeutics's return on equity of 10.9%.

Cardiff Oncology has a consensus price target of $12.07, signalling upside risk potential of 173.11%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 879.02%. Given that Protalix BioTherapeutics has higher upside potential than Cardiff Oncology, analysts believe Protalix BioTherapeutics is more attractive than Cardiff Oncology.

Cardiff Oncology has a beta of 1.516, which suggesting that the stock is 51.624% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Cardiff Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardiff Oncology pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Cardiff Oncology quarterly revenues are $109K, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Cardiff Oncology's net income of -$13.4M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Cardiff Oncology's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 35.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardiff Oncology is 399.21x versus 2.01x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.